Summary of Safety and Effectiveness
Liquichek Microalbumin Control

K072835

1.0 Submitter

Bio-Rad Laboratories
9500 Jeronimo Road,
Irvine, California 92618-2017
Telephone: (949) 598-1200
Fax: (949) 598-1555

DEC 1 1 2007

Contact Person

Suzanne Parsons
Regulatory Affairs Specialist
Telephone: (949) 598-1467

Date of Summary Preparation

September 27, 2007

2.0 Device Identification

Product Trade Name:	Liquichek Microalbumin Control
Common Name:	Multi-Analyte Controls, (Assayed and unassayed)
Classifications:	Class I
Product Code:	JJY
Regulation Number:	21 CFR 862.1660

3.0 Device to Which Substantial Equivalence is Claimed

Liquichek Urine Chemistry Control
Bio-Rad Laboratories
Irvine, California

Docket Number: K020817

4.0 Description of Device

Liquichek Microalbumin Control is prepared from human urine with added constituents of human, pure chemicals, preservatives and stabilizers. The control is provided in liquid form for convenience.

5.0 Statement of Intended Use

Liquichek Microalbumin Control is intended for use as an assayed quality control urine to monitor the precision of laboratory procedures listed in the package insert.

6.0 Comparison of the new device with the Predicate Device

Liquichek Microalbumin Control claims substantial equivalence to the Liquichek Urine Chemistry Control currently in commercial distribution (K020817). The new Liquichek Microalbumin Control contains claims only for microalbumin and creatinine.

Table 1. Similarities and Differences between new and predicate device.

Characteristics	Bio-Rad Laboratories Liquichek Microalbumin Control (New Device)	Bio-Rad Laboratories Liquichek Urine Chemistry Control (Predicate Device)
Similarities		
Intended Use	Liquichek Microalbumin Control is intended for use as assayed quality control urine to monitor the precision of laboratory testing procedures for analytes listed in the package insert.	Liquichek Urine Chemistry Control is intended for use as assayed quality control urine to monitor the precision of laboratory testing procedures for analytes listed in the package insert.
Form	Liquid	Liquid
Matrix	Human urine based	Human urine based
Shelf Storage Claim (Unopened)	2 to 8°C Until expiration date	2 to 8°C Until expiration date
Open Vial Claim	30 days at 2-8°C	30 days at 2-8°C
Differences		
Analytes	Contains: Microalbumin and creatinine Does not contain: – Amylase – Calcium – Chloride – Cortisol – Glucose – Magnesium – Osmolality – pH – Phosphorus – Potassium – Pregnancy – Protein, Total – Sodium – Specific Gravity – Urea – Urea Nitrogen – Uric Acid	Contains: – Amylase – Calcium – Chloride – Cortisol – Creatinine – Glucose – Magnesium – Microalbumin – Osmolality – pH – Phosphorus – Potassium – Pregnancy – Protein, Total – Sodium – Specific Gravity – Urea – Urea Nitrogen – Uric Acid

7.0 Summary of Performance Data

Stability studies have been performed to determine the open vial stability and shelf life for the Liquichek Microalbumin Control. Product claims are as follows:

7.1 Open vial: Once the control material is opened, all analytes will be stable for 30 days when stored tightly capped at 2-8 °C.

7.2 Shelf Life: Two years when stored at 2-8 °C.

Real time studies will be ongoing to support the shelf life of this product.
All supporting data is retained on file at Bio-Rad Laboratories.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

DEC 1 1 2007

Bio-Rad Laboratories
Diagnostics Group
c/o Ms. Suzanne Parsons
Regulatory Affairs Specialist
9500 Jeronimo Road
Irvine, CA 92618-2017

Re: k072835
Trade Name: Liquichek™ Microalbumin Control Levels 1 & 2
Regulation Number: 21 CFR 862.1660
Regulation Name: Quality control material (assayed and unassayed).
Regulatory Class: Class I
Product Code: JJY
Dated: October 01, 2007
Received: November 16, 2007

Dear Ms. Parsons:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M. Cooper, M.S., D.V.M.

Jean M. Cooper, M.S., D.V.M.
Director
Division of Chemistry and Toxicology
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K072835

Device Name: **Liquichek Microalbumin Control**

Indications For Use: **Liquichek Microalbumin Control is intended for use as an assayed quality control material to monitor the precision of laboratory testing procedures for the analytes listed in the package insert.**

Prescription Use __X__ AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Carol C. Benson
Division Sign-Off

Office of In Vitro Diagnostic Device
Evaluation and Safety

K072835